Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn or 69 kda omp); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml; diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid vaccine 8 mcg / 0.5 ml; inactivated polio virus (ipv) type 3 32 du / 0.5 ml; inactivated polio virus (ipv) type 1 40 du / 0.5 ml; inactivated polio virus (ipv) type 2 8 du / 0.5 ml - bacterial and viral vaccines, combined - for booster vaccination against diphtheria, tetanus and pertusis and poliomyelitis of individuals from the age of four years onwards. boostrix polio is not intended for primary immunisation. the administration of boostrix polio should be based on official recommendations.

Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - mepolizumab - אבקה להכנת תמיסה לזריקה - mepolizumab 100 mg - mepolizumab

Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - belantamab mafodotin - אבקה להכנת תמיסה מרוכזת לעירוי - belantamab mafodotin 100 mg - belantamab

Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - live attenuated measles virus; live attenuated mumps virus; live attenuated rubella virus - אבקה וממס להכנת תמיסה להזרקה - live attenuated mumps virus 10^3.7 ccid50; live attenuated rubella virus 10^3.0 ccid50; live attenuated measles virus 10^3.0 ccid50 - rubella, combinations with mumps, live attenuated - rubella, combinations with mumps, live attenuated - priorix is indicated for active immunisation of children from the age of 9 months or older, adolescents and adults against measles, mumps and rubella.

Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - neisseria meningitides group b strain nz98/254; neisseria meningitidis group b fhbp fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b nhba fusion protein - תרחיף להזרקה - neisseria meningitides group b strain nz98/254 25 mcg; neisseria meningitidis group b fhbp fusion protein 50 mcg; neisseria meningitidis group b nada protein 50 mcg; neisseria meningitidis group b nhba fusion protein 50 mcg - meningococcus b, outer membrane vesicle vaccine

Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen

Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - varicella zoster virus glycoprotein e antigen - אבקה ותרחיף להכנת תרחיף להזרקה - varicella zoster virus glycoprotein e antigen 50 mcg - zoster, purified antigen

Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - ranitidine as hydrochloride - סירופ - ranitidine as hydrochloride 150 mg / 10 ml - ranitidine - ranitidine - h2 receptor antagonist. for treatment of duodenal ulcer and benign gastric ulcer, including that associated with nsaid agents. post-operative ulcer, oesophageal reflux disease and zollinger-ellison syndrome. prophylaxis of stress ulceration in seriously ill patients. before general anaesthesia in patients considered to be of risk acid aspiration (mendelson's syndrome).

Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - ambrisentan - טבליות מצופות פילם - ambrisentan 5 mg - ambrisentan - volibris is indicated for the treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity . efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.

Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - ambrisentan - טבליות מצופות פילם - ambrisentan 10 mg - ambrisentan - volibris is indicated for the treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity . efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.